Shelf 029 entries9 published
Metabolic peptides
Incretin and amylin analogues, and older metabolic fragments. This is the shelf where research compounds and licensed medicines sit side by side, so every entry says plainly which is which.
Entries
On this shelf
| No. | Compound | Parent or target | Evidence | Status |
|---|---|---|---|---|
| 0007 | Semaglutide31 residues · 4113.6 g/mol | GLP-1 | Licensed medicine; large phase 3 trials | Published |
| 0008 | Tirzepatide39 residues · 4813.5 g/mol | GIP / GLP-1 | Licensed medicine; large phase 3 trials | Published |
| 0005 | Retatrutide39 residues · ≈4731 g/mol | GIP / GLP-1 / glucagon | Phase 3 reported 2026; not approved | PublishedIn store as GLP-3 |
| 0020 | CagrilintideAmylin analogue | Amylin | Phase 3 with semaglutide | Published |
| 0019 | AOD-960416 residues | Growth hormone 176–191 | Small human trials; development stopped | Published |
| 0018 | PT-141Cyclic heptapeptide | Melanocortin | Licensed in the US as bremelanotide | Published |
| 0027 | Survodutide29 residues · 4231.7 g/mol | Glucagon / GLP-1 | Phase 3 results 2026; not licensed | Published |
| 0028 | Mazdutide34 residues · 4563.1 g/mol | GLP-1 / glucagon | Licensed in China since 2025 | Published |
| 0029 | OrforglipronSmall molecule · 883.0 g/mol | GLP-1 | Licensed medicine; oral, not a peptide | Published |
Compare
Side by side
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptors | GLP-1 | GIP, GLP-1 | GIP, GLP-1, glucagon |
| Top weight change in a published trial | −14.9% at 68 weeks | −20.9% at 72 weeks | Up to −28% at 80 weeks (announced) |
| Licensed | UK, EU, US | UK, EU, US | Nowhere |
| In our store | No | No | Not at present |
| WADA | Not prohibited | Not prohibited | S0 by default |
Semaglutide and tirzepatide are licensed prescription medicines. We do not sell semaglutide. Tirzepatide and GLP-3 (retatrutide) are in the store as lot-tested research materials for laboratory use only.
Compare